⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Xiu-Zhi Zhu Hu-Yun-Long Zhang Yi-Fan Zhou Yi-Yu Chen Tong Fu Ming-Liang Jin Ya-Xin Zhao Yi-Fan Xie Xiaohua Zeng Xi Jin Yi‐Zhou Jiang Zhi‐Ming Shao

View at Publisher

Ask AI

Bookmark

Share

Key Points

Endocrine therapy improved viability in PDOs more effectively for specific subtypes of breast cancer.
Precision treatment approaches demonstrate significant benefits over traditional methods for HR+/HER2− cases.
Observational analysis of PDOs grouped by subtype reveals patterns in treatment efficacy.
Findings support tailored therapies, suggesting advancements in individualizing treatment for breast cancer patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis of viability in PDOs following endocrine therapy highlights potential for precision treatment.

Abstract

Fig. S1 Viability of PDOs grouped by subtype treated with endocrine therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcb42 https://doi.org/10.1158/0008-5472.30363487

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
2Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
3Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
4Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
5Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025

Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025